Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna's COVID-19 Vaccine Development Neglects The Importance Of T Cells

Breakout biotech stock Moderna has been all over the map thanks to a series of headlines related to a potential coronavirus vaccine. Here's how options traders are betting it all plays out.

Here's how options traders are betting Moderna's wild week will end

MRNA stock is a big bet right now, but it also reaps huge rewards if Moderna’s promising trials hold up to further testing.
The post The Rewards Outweigh the Risks for Moderna Stock appeared first on InvestorPlace.

The Rewards Outweigh the Risks for Moderna Stock

Moderna stock is up by about 270% year-to-date, as it emerged a front runner in the race to develop a vaccine for the highly contagious novel-Coronavirus. Earlier this week, Moderna said that its vaccine candidate - mRNA-1273- produced protective antibodies in a small group of healthy volunteers.

What If Moderna’s COVID-19 Vaccine Fails?

Moderna, a Boston-based ex-unicorn that has successfully developed and marketed as many drugs as you have, turned itself from a $6 billion midcap stock to a $27 billion large cap stock over the space of a few months and a handful of press releases.

Moderna’s Announcement Was Great News - Just Not For The Reason You Think

Gilead Sciences

Some recent news items offer clues as to how investors will respond if and when the FDA approves a SARS-CoV-2 vaccine.

How a Coronavirus Vaccine Might Move the Stock Market

We don't know which vaccine will succeed. Therefore investors in MRNA stock should proceed with caution.

The Virus Vaccine Race is Fueling Moderna Stock to New Highs

Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

Target

Lowe's

McKesson

Target, Lowe's, McKesson and Moderna were our top stock trades for Thursday. That said, here's what the charts look like now.

4 Top Stock Trades for Thursday: LOW, TGT, MRNA, MCK

More Than A Bear Market Rally

The company put out the extent of data it had available, Moderna Chairman Noubar Afeyan tells CNBC.

Moderna would never release coronavirus vaccine data different from 'reality,' chairman says

Morgan Stanley, which recently named Moderna Inc (NASDAQ: MRNA) as one of the likeliest candidates to succeed in the coronavirus vaccine race, reviewed the interim Phase 1 data released by the company Monday.

Moderna Analyst Says Coronavirus Vaccine Candidate Has 65% Chance Of Success

Moderna took advantage of that positive vibe to issue 17.6 million shares at a price of $76.00 Monday evening in an offering solely led by Morgan Stanley.

Exercise Caution In Playing Morgan Stanley’s Moderna Shuffle

Moderna (MRNA) shares decline following a report raising questions on clinical data announced earlier this week related to its coronavirus vaccine.

Moderna Declines on Skepticism on Coronavirus Vaccine Data

Sorrento Therapeutics Inc

Which stock wins in a match-up between these two high-flying biotechs with promising COVID-19 programs?

Better Coronavirus Stock:  Moderna vs.  Sorrento Therapeutics

Beyond Meat

Ceridian HCM Holding Inc.

DocuSign

Elanco Animal Health Inc

AXA Equitable Holdings Inc

Pinduoduo Inc - ADR

Spotify

Uber

Slack

IPO Index Touches All-Time High, Fueled By #4 Holding Moderna

Moderna, Inc.’s (NASDAQ: MRNA) claims on achieving a dose-dependent increase in immunogenicity in Phase 1 trials of its COVID-19 vaccine candidate, mRNA-1273, are not backed by sufficient data, according to vaccine experts.

Moderna Vaccine Trial Missing Data To Judge Vaccine Efficacy, Experts Say

They have to publish a scientific paper, opting for issuing press releases instead.

Scientists Raise Questions About Moderna Vaccine In Market-Shaking Report

A warning does not necessarily have to become a full-blown sign to head for the exits. But it is, nevertheless, a warning.

Moderna and Volatility Index Flash Warning for Investors

Data from a small, early-stage safety trial testing Moderna Inc's  experimental COVID-19 vaccine does not provide the critical data needed to assess its effectiveness, health-focused Stat News reported on Tuesday, citing experts.

Early data on Moderna's COVID-19 vaccine insufficient: Stat News

MRNA stock continues to reach new highs, leaving investors wondering if Moderna's rally is sustainable over the long term.
The post Does Moderna Stock’s Rally Hold Up Under the Microscope?

Does Moderna Stock’s Rally Hold Up Under the Microscope?

Heavy hearts soared Monday with news that Moderna's Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be generating an immune response in Phase 1 trial subjects.

Vaccine experts say Moderna didn't produce data critical to assessing Covid-19 vaccine

Wall Street analysts are cranking up their price targets on the biotech in response to early clinical trial results for its coronavirus vaccine candidate.

Is Moderna Stock Really Headed to $112?

Biotech stocks are often high-risk, high-reward investments that have binary outcomes based on one or a handful of drug or device candidates in development.

Moderna Short Sellers Take $450M Hit Following Coronavirus Vaccine Data

Investor euphoria on the company’s vaccine candidate may not be warranted

News for Moderna Stock (MRNA)